Cue Biopharma is a clinical-stage biopharmaceutical company developing precision immuno-engineered therapies for allergic and autoimmune diseases. The company operates the Immuno-STAT platform, which selectively modulates disease-specific T cells to restore immune balance. Its pipeline includes the CUE-400 series for autoimmune conditions, led by CUE-401, a bifunctional fusion protein targeting TGF-β and IL-2 signaling to induce regulatory T cells. The CUE-500 series focuses on targeted cell depletion, with CUE-501 designed to deplete pathogenic B cells in autoimmune diseases. The CUE-100 series addresses oncology indications, including CUE-101 for HPV-positive cancers and CUE-102 for WT1-expressing cancers. Additionally, CUE-221 is an anti-IgE antibody for IgE-mediated allergic diseases, currently in Phase 2b/3 studies for chronic spontaneous urticaria. Strategic partnerships include a license agreement with Boehringer Ingelheim for CUE-501 and a collaboration with ImmunoScape for the CUE-100 series.

Summarised from the company's own disclosures, fiscal year ended Mar 2026

Industry Biotechnology Homepage cuebiopharma.com
Sector Healthcare IR page cuebiopharma.com
Tags
autoimmune diseases, allergic diseases, t cell modulation, regulatory t cells, b cell depletion, oncology, ige-mediated disorders, bifunctional proteins, immune tolerance, clinical-stage, Immuno-STAT, CUE-401, CUE-501, CUE-101, CUE-102, CUE-221, CUE-400 series, CUE-500 series, CUE-100 series
Press page cuebiopharma.com/news

Metrics

Valuation  
Market cap $ 216.433M
Market cap (USD) $ 216.433M
P/E -0.93
PEG —
P/BV 5.64
P/S 6.07
P/OCF -4.24
P/FCF -4.23
Dividend yield —
Turnover / mcap —
Returns  
ROE -121.1%
ROI -1,681.5%
ROIC -1,258.8%
Profit margin -96.9%
Growth  
Revenue growing Yes
Profits growing Yes
Revenue up 3y Yes
Revenue up 5y No
Earnings growth 3y (net profit CAGR) —
Quality  
Profitable No
Margin expanding Yes
Buying back stock No
Diluting (TTM) No
Debt/Equity —
Podcast bulls (TTM) Sign up
Podcast bears (TTM) Sign up
Podcast sentiment (TTM) Sign up
Podcast sentiment % (TTM) Sign up
News sentiment (TTM) 13
Quality score -29.4%
Insiders  
Buys, 1w Sign up
Buys, 1m Sign up
Buys, 1y Sign up
Sells, 1w Sign up
Sells, 1m Sign up
Sells, 1y Sign up

Sign up to see this company's insider trades

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018 FY 2017
Revenue 27.466M 9.287M 5.49M 1.245M 14.941M 3.154M 3.458M 1.143M —
Net profit -26.602M -40.674M -50.733M -53.01M -44.161M -44.785M -36.699M -38.98M -23.234M
Free cash flow -21.864M -36.395M -39.961M -41.977M -39.75M -33.089M -30.843M -28.265M -13.171M

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018 FY 2017
Share price 0.31 1.03 2.76 3.75 18.02 12.64 15.74 4.64 7.5
Price performance 12m -0.7 -0.63 -0.26 -0.79 0.43 -0.2 2.39 -0.38 —

Filed figures

Figure Dec 2016 Dec 2017 Dec 2018 Dec 2019 Dec 2020 Dec 2021 Dec 2022 Dec 2023 Dec 2024 Dec 2025
Balance sheet detail
Trade receivables (USD) — — — 754,898 1.42M 3.14M 57,252 1.7M 945,000 5.55M
↳ YoY growth +87.8% +121.7% -98.2% +2,865.8% -44.3% +486.9%
↳ 5y CAGR +4.6% +31.4%
Borrowings, current (USD) — — — — — — 2.07M 4.04M 37,000 —
Borrowings, non-current (USD) — — — — — 0.00 8.03M 4.2M 0.00 —
Lease liabilities (USD) — — — 5.8M 7.15M 10.1M 9.32M 6.53M 4.54M 4.2M
Cash and deposits (USD) 14.9M 63.5M 20.8M 44.3M 74.9M 64.4M 51.6M 48.5M 22.5M 27.1M
Right-of-use assets (USD) — — — 5.34M 6.77M 9.81M 9.2M 6.32M 4.37M 4.07M
Net debt (borrowings + leases - cash) (USD) — — — — — -54.3M -32.2M -33.7M -17.9M —
Cash flow detail
Operating cash flow (USD) -5.97M -12.2M -26.4M -30.8M -32.5M -38.8M -41.8M -40M -36.3M -21.7M
Purchases of property, plant and equipment (USD) 515,979 1.03M -1.85M -46,353 -595,259 -913,039 -170,746 0.00 -66,000 -177,000
Purchases of intangible assets (USD) 0.00 175,000 — — — — — — — —
Change in receivables (cash effect) (USD) — — — -754,898 -662,584 -1.73M 3.09M -1.64M 753,000 -4.6M
Change in payables (cash effect) (USD) 372,148 561,586 376,147 -1.15M 741,265 520,398 83,110 770,000 -678,000 1.13M
Share buybacks (cash effect) (USD) — — — -91,027 -271,051 -750,183 -199,873 0.00 — —
Interest paid (cash effect) (USD) — — — — — 0.00 -570,347 -1M -669,000 -214,000
Income taxes paid (cash effect) (USD) — — -825,000 -412,500 — — — — 0.00 -500,000
Share-based compensation (USD) 889,556 2.78M 7.17M 6.52M 10.5M 11.5M 9.5M 8.18M 6.85M 4.74M
Operating cash flow before change in receivables (USD) — — — -30M -31.8M -37.1M -44.9M -38.3M -37.1M -17.1M
Free cash flow (OCF - PPE - intangibles) (USD) -6.48M -13.4M -28.3M -30.8M -33.1M -39.8M -42M -40M -36.4M -21.9M
Income detail
Research and development expense (USD) 5.69M 18.9M 28.5M 27.5M 33.5M 41.3M 38.6M 40.8M 36.3M 37.7M
↳ 5y CAGR +86.1% +48.7% +15.3% +7.4% +5.7% +2.4%
Total comprehensive income (USD) — -23.2M -39M -36.7M -44.8M -44.2M -53.1M -50.6M -40.7M —
Comprehensive income to owners (USD) — -23.2M -39M -36.7M -44.8M -44.2M -53.1M -50.6M -40.7M —
Reported May 14, 2018 Mar 14, 2019 May 8, 2019 Mar 12, 2020 Mar 9, 2021 Mar 21, 2023 Mar 21, 2023 Mar 28, 2024 Mar 16, 2026 Mar 16, 2026

Sign up to see institutional holdings

Sign Up

Podcast Mentions

Sign up to see podcast mentions and sentiment

Sign Up

•CUE-221 Phase 2 chronic spontaneous urticaria (CSU) findings highlight differentiated clinical benefit and potential to expand the addressable patient population in CSU and food allergy

•CUE-401 enters clinical development with initiation of first-in-human dosing, achieving key 2026 milestone

•Operating results reflect expenditures related to initiation of clinical development program expenses and non-cash charges

BOSTON, November 16, 2026 – Cue Biopharma, Inc. (Nasdaq: CUE), a clinical stage biopharmaceutical company targeting transformative therapies for immune-mediated diseases, today reported third quarter 2026 financial results as well as recent business highlights.

“We are seeing exciting momentum across our portfolio,” said Pasha Sarraf, M.D., Ph.D., chairman of the board of Cue Biopharma. “We believe CUE-221 has the potential to redefine treatment of IgE-mediated diseases by delivering deeper, more durable disease control and expanding the population of patients who can benefit from anti-IgE therapy.

September 20, 2026

Results support potential for differentiated clinical impact for patients suffering from chronic hives and advancement to Phase 2b/3 registration enabling study

  • Primary endpoint and the key secondary endpoint were met with high statistical significance and CUE-221 demonstrated an overall favorable safety profile

  • Clinically different efficacy profile observed relative to XOLAIR® (omalizumab) highlights potential for a fundamental mechanism-based biological difference

  • Cue Biopharma to host conference call on Monday, September 21, at 8:00 a.m. EDT

BOSTON, Sept. 20, 2026 (GLOBE NEWSWIRE) — Cue Biopharma (Nasdaq: CUE), a clinical-stage biopharmaceutical company targeting transformative therapies for immune-mediated diseases, today announced positive topline results from the Phase 2 clinical trial of CUE-221 (UB-221) conducted in China by Genesis Life Sciences, a related company of Ascendant Health Limited (Ascendant). The trial enrolled 145 participants with moderate to severe chronic spontaneous urticaria (CSU), a disease resulting in chronic hives, that remained inadequately controlled despite treatment with H1 antihistamines.

“We are excited to share these positive results which we believe establish CUE-221 as a potential best therapeutic option for patients suffering with chronic spontaneous urticaria,” said Shao-Lee Lin, M.D., Ph.D., President and Chief Executive Officer of Cue Biopharma. “These findings reinforce our enthusiasm for the precision engineered, unique dual mechanism of action of CUE-221, reflecting science that is truly differentiated. Based on the strength of these data, we are working toward the rapid initiation of a Phase 2b/3 study in CSU and continuing to advance a planned Phase 2 study in food allergy. We thank the patients, investigators, and study staff, all of whom made these results possible. We look forward to presenting the complete data set including PK and IgE analyses from this 36-week study at an upcoming scientific meeting.”

Phase 2 CSU Study Topline Results

The Phase 2 multicenter, randomized, double-blind, placebo and active comparator-controlled study was conducted in China and included a 16-week treatment period with a 20-week follow-up period post-treatment. Patients were randomized in a 2:2:2:1:1 ratio across five treatment groups to either subcutaneously deliver CUE-221 at 4 mg/kg, 2 mg/kg, or 1 mg/kg Q4W, or placebo Q4W, or omalizumab 300 mg Q4W. The primary endpoint was the proportion of patients who achieved HSS7=0 at week 12. A key secondary endpoint assessed complete response, defined as the proportion of patients who achieved UAS7=0 at week 12. The study was designed to test superiority over placebo. Omalizumab was included to enable comparative efficacy without planned statistical testing.

The primary endpoint of percentage of patients with HSS7=0 at week 12 was dose-responsive and met at all dose levels. The key secondary endpoint of percentage of patients with UAS7=0 at week 12 was dose responsive and met statistical significance at the 4 mg/kg highest dose level.

| | | | | | |

| --- | --- | --- | --- | --- | --- |

| Primary Endpoint of HSS7=0 at Week 12 | | | | | |

| | CUE-221 (Q4W) | | | Placebo Q4W | Omalizumab Q4W |

| | 4 mg/kg (N=35) | 2 mg/kg (N=36) | 1 mg/kg (N=37) | (N=18) | 300 mg (N=17) |

| Complete Resolution of Hives (HSS7=0) | 54% | 53% | 43% | 11% | 41% |

| 95% Confidence Interval | (37%, 71%) | (36%, 70%) | (27%, 61%) | (1%, 35%) | (18%, 67%) |

| P-values (vs placebo) | p < 0.005 | p < 0.005 | p < 0.05 | NA | Not Tested |

P-values based on Fisher’s exact test; Clopper-Pearson 95% confidence interval

| | | | | | |

| --- | --- | --- | --- | --- | --- |

| Key Secondary Endpoint of UAS7=0 at Week 12 | | | | | |

| | CUE-221 (Q4W) | | | Placebo Q4W | Omalizumab Q4W |

| | 4 mg/kg (N=35) | 2 mg/kg (N=36) | 1 mg/kg (N=37) | N=18 | 300 mg (N=17) |

| Complete Response (UAS7=0) | 46% * | 39% | 38% | 11% | 29% |

| 95% Confidence Interval | (29%, 63%) | (23%, 57%) | (23%, 55%) | (1%, 35%) | (10%, 56%) |

* p<0.05 P-values based on Fisher’s exact test; Clopper-Pearson 95% confidence interval

The percentage of participants who achieved HSS7=0 further increased beyond the Week 12 primary endpoint, peaking at Week 22 across all CUE-221 dose groups. After a last dose was administered for all groups at Week 16, clinically meaningful benefit was maintained for up to 12 weeks off treatment (through week 28) at the 4 mg/kg dose level. A higher rate of complete resolution of hives was observed for the 4 mg/kg dose group relative to the lower dose groups and placebo, and post hoc analysis at Week 28 demonstrated a statistically significant difference versus omalizumab (delta = 36%), supporting the premise of fundamental difference between CUE-221 and omalizumab with respect to impacts on disease biology.

| | | | | | | |

| --- | --- | --- | --- | --- | --- | --- |

| Complete Resolutions of Hives at Primary Endpoint, Peak Effect, and 12 Weeks Off Drug | | | | | | |

| | CUE-221 (Q4W) | | | Placebo Q4W | Omalizumab Q4W | CUE 4mg/kg vs.Omalizumab |

| Time | 4 mg/kg | 2mg/kg | 1 mg/kg | Placebo | 300 mg | Δ in Percent |

| Week 12 Primary | 54% | 53% | 43% | 11% | 41% | 13% |

| Week 22 Peak Effect | 69% | 61% | 57% | 11% | 41% | 28% |

| Week 28 12 weeks off drug | 60% | 31% | 24% | 11% | 24% | 36% * |

* p<0.05 P-values based on Fisher’s exact test

Demographics and baseline disease characteristics were generally well balanced across treatment groups. CUE-221 demonstrated a favorable safety profile. There were no treatment-related serious adverse events and no cases of hypersensitivity reactions including anaphylaxis. Injection site reactions (ISR) were infrequent, only one ISR was > grade 1, and none led to study discontinuation.

“The results of the Phase 2 CUE-221 study in patients with CSU are particularly notable,” said Dale Umetsu, M.D., Ph.D., Clinical Professor of Medicine and former Chief of the Allergy and Immunology Division, Stanford University, Clinical Professor of Pediatrics, University of California, San Francisco and prior Global Lead for XOLAIR development. “First, the results after 12 weeks of treatment, after three doses, appear to indicate that CUE-221 was better than XOLAIR for CSU at all dose levels tested. Moreover, there was persistent improvement with the 4 mg/kg dose at week 28, which was 12 weeks off treatment, significantly better than that off of standard XOLAIR dosing. Finally, the safety data analyzed so far, show no major safety issues, which is not unexpected from an anti-IgE mAb.”

Dr. Umetsu added, “These results suggest that CUE-221, like XOLAIR is designed to prevent IgE from binding to FceR1 but unlike XOLAIR, allows IgE to bind to CD23, may represent a critical advancement over XOLAIR. The results support that the effects of CUE-221 on IgE function could result in substantial efficacy in CSU that persists for several months, even after dosing ends. Since XOLAIR has represented the clear standard for all other CSU therapies, the possibility that CUE-221 may represent a clear improvement above that of XOLAIR is most impressive. That improvement in efficacy may be directly relevant for food allergy, another area where XOLAIR currently prevails as the standard-of-care.“

“I am very pleased to see these outstanding results from the UB-221 Phase 2 CSU trial,” said Tse-Wen Chang, Ph.D., innovator of XOLAIR as well as UB-221 and an international expert in IgE biology. “The UB-221 data provide clear clinical evidence validating the molecule’s design to not only directly neutralize IgE, but also to create a next-generation approach to eliminate the production of new IgE over time. This fundamental difference in biological mechanism that is now clinically evident cannot be reached by giving higher doses or more potent IgE neutralization. Having invented several novel IgE-targeting molecules that ultimately led to the creation of UB-221, I am encouraged by these emerging data and the potential for this approach to offer a meaningfully different path toward a functional treatment for IgE-mediated diseases.”

Webcast and Conference Call

Cue Biopharma will host a conference call and webcast on Monday, September 21 at 8:00 a.m. EDT to present the results. The event will be webcast live and can be accessed via the attached link below. https://edge.media-server.com/mmc/p/mjexxy37 

About Dale Umetsu, M.D., Ph.D.

Dale Umetsu, M.D., Ph.D., Former chief of the allergy immunology division and tenured professor of pediatrics at Stanford University, and Former Prince al Saud Professor of Pediatrics AT Harvard Medical School. Dr. Umetsu also led global development of XOLAIR and the approval of XOLAIR for CSU and food allergy while at Genentech. Currently, he serves as a clinical professor of pediatrics at the University of California, San Francisco.

About Tse-Wen Chang, Ph.D.

Tse-Wen Chang, Ph.D., is a Taiwanese immunologist and pioneer in anti-IgE therapy. His early research into the immunoglobulin E (IgE) pathway and antibody-based therapeutics contributed to the development of omalizumab (XOLAIR), which is approved for the treatment of severe allergic asthma and severe chronic spontaneous urticaria. Dr. Chang is a cofounder of Tanox, a biopharmaceutical company focused on anti-IgE therapies for allergic diseases. He previously served as Dean of the College of Life Sciences at National Tsing Hua University in Taiwan and as Distinguished Research Fellow at the Genomics Research Center, Academia Sinica.

About Chronic Spontaneous Urticaria

CSU is a chronic inflammatory skin disease driven in part by type 2 inflammation, which causes sudden and debilitating hives and recurring itch. CSU is typically treated with H1 antihistamines, medicines that target H1 receptors on cells to control symptoms of itch and urticaria. However, the disease remains uncontrolled despite antihistamine treatment in many patients, some of whom are left with limited alternative treatment options. These individuals continue to experience symptoms that can be debilitating and significantly impact their quality of life.

About CUE-221

CUE-221 (Ascendant-221, UB-221) is a humanized anti-IgE IgG1 monoclonal antibody designed with a precision engineered dual mechanism of action. CUE-221 binds to IgE at sites that are distinct from the binding sites for other anti-IgE monoclonal antibodies. In doing so, it maintains the capacity of total IgE to bind the CD23 receptor at the surface of B cells, resulting in reduced IgE synthesis. Therefore, CUE-221 is a functionally distinct novel anti-IgE antibody designed to not only neutralize free IgE with high potency, but also prevents the synthesis of new IgE which could ultimately result in functional cure if IgE is eradicated. The CUE-221 Phase 2 clinical trial in CSU produced positive topline results and clinical evidence providing initial validation of the clinical potential of a precision engineered anti-IgE dual mechanism of action. The study also demonstrated fundamental biological differences compared to current therapies. Based on these data, we are planning to advance CUE-221 in a Phase 2b/3 study in chronic spontaneous urticaria and in a Phase 2 study in food allergy.

CUE-221 (UB-221) was innovated by Dr. Chang Tse Wen, a pioneer in the field of anti-IgE therapy, while serving as a Fellow of Academia Sinica. UB-221 was originally developed by United Biopharma (Holdings) Co., Ltd. (“United Biopharma”) with rights allocated between two of United Biopharma’s related companies, Genesis Life Sciences (“Genesis”) (China, Hong Kong, Macau and Taiwan, where Genesis continues development of the antibody under the name UB-221) and Ascendant Health Limited (“Ascendant”) (rest of world). Under an exclusive license agreement with Ascendant, Cue Biopharma obtained exclusive development, manufacturing, and commercialization rights in Ascendant’s rest of world territories.

About Cue Biopharma

Cue Biopharma (Nasdaq: CUE) is a clinical stage biopharmaceutical company focused on advancing a portfolio of potentially transformative therapies designed to enable functional cures across immunological disorders. Its lead asset, CUE-221, is a novel anti-IgE antibody with a dual mechanism of action design, moving into Phase 2b/3 development for allergic diseases. In addition, Cue developed the Immuno-STAT® platform which selectively targets disease-specific T cells in vivo without broad immune modulation. Its lead autoimmune candidate, CUE-401, has an investigational new drug application pending in the U.S. for a Phase 1 clinical trial. CUE-401 is designed to regulate inflammation and drive Treg-mediated tolerance. Cue is led by an experienced management team with deep expertise in identifying, acquiring, and advancing promising drug candidates.

About Ascendant Health Limited

Ascendant is a privately held biotechnology company committed to delivering transformative solutions to patients globally.

About Genesis Life Sciences

Genesis Life Sciences focuses on the innovative development of monoclonal antibody drugs. It is a biopharmaceutical company with a product line in late-stage clinical trials, specializing in the development of innovative monoclonal antibody drugs applicable to chronic infectious diseases, allergic diseases, and autoimmune diseases. Closely aligned with key national research projects and market demand, the company has introduced highly promising monoclonal antibody products, leveraging internal research capabilities and support from expert teams across various fields to accelerate the product launch and sales process. We care about human health and well-being, focus on unmet patient needs, and drive monoclonal antibody development through innovative thinking, ultimately sharing our results with partners and the public, striving to provide the best treatment for patients.

*XOLAIR® is a registered trademark of Novartis AG.

Cautionary Note Regarding Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements include, but are not limited to, those regarding the potential of CUE-221, including its potential future benefit to patients, the company’s plans with respect to CUE-221, including the initiation of a Phase 2b/3 clinical trial in CSU and a Phase 2 clinical trial in food allergy and the timing thereof, the company’s expectations regarding the presentation of full clinical data from the Phase 2 CUE-221 trial, the company’s growth, and the company’s business strategies, plans, and prospects.

Forward-looking statements, which are based on certain assumptions and describe the company’s future plans, strategies and expectations, can generally be identified by the use of forward-looking terms such as “believe,” “expect,” “may,” “will,” “should,” “would,” “could,” “seek,” “intend,” “plan,” “goal,” “project,” “estimate,” “anticipate,” “strategy,” “future,” “likely,” “promise,” “potential” or other comparable terms, although not all forward-looking statements contain these identifying words. All statements other than statements of historical facts included in this press release regarding the company’s strategies, prospects, financial condition, operations, costs, plans, and objectives are forward-looking statements. Important factors that could cause the company’s actual results and financial condition to differ materially from those indicated in the forward-looking statements include, among others, the company’s ability to maintain and establish collaboration, licensing and other arrangements; the company’s limited operating history, limited cash and a history of losses; the company’s ability to achieve profitability; potential setbacks in the company’s research and development efforts for its current and future drug product candidates, including negative or inconclusive results from its preclinical studies or clinical trials or the company’s ability to replicate in later clinical trials positive results found in preclinical studies and early-stage clinical trials of its product candidates; serious and unexpected drug-related side effects or other safety issues experienced by participants in clinical trials; potential challenges associated with clinical trials conducted in China and the company’s access to, and acceptability of, the data therefrom; its ability to secure required U.S. Food and Drug Administration (“FDA”) or other governmental approvals for its product candidates and the breadth of any approved indication; delays and changes in regulatory requirements, policy and guidelines including potential delays in submitting required regulatory applications to the FDA; the company’s reliance on licensors, collaborators, contract research organizations, suppliers and other business partners; the company’s ability to obtain adequate financing to fund its business operations in the future; the company’s ability to maintain and enforce necessary patent and other intellectual property protection; competitive factors; general economic and market conditions and the other risks and uncertainties described in the Risk Factors and Management’s Discussion and Analysis of Financial Condition and Results of Operations sections of the company’s most recently filed Annual Report on Form 10-K and any subsequently filed Quarterly Report(s) on Form 10-Q. Any forward-looking statement made by the company in this press release is based only on information currently available to the company and speaks only as of the date on which it is made. The company undertakes no obligation to publicly update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise. 

August 14, 2026

  • _Announced recent Investigational New Drug (IND) submission to the FDA for CUE-221 in food allergy applications

_

  • _Completed a $50 million private placement (PIPE) to further fund clinical development and the portfolio with significant potential for value-inflection

_

  • _Strengthened the leadership team with the appointments of the Chief Medical Officer and Head of R&D and the Chief Financial Officer

_

  • Operating results reflected higher expenditures related to the licensing and initiation of the CUE-221 development program, driven by one-time non-cash charges and acquisition-related payments

BOSTON, Aug. 14, 2026 (GLOBE NEWSWIRE) — Cue Biopharma, Inc. (Nasdaq: CUE), a clinical stage biopharmaceutical company targeting transformative therapies for immune-mediated diseases, today reported second quarter 2026 financial results as well as recent business highlights.

“I am pleased with our progress this quarter, advancing our pipeline and strengthening our position for long-term growth,” said Shao-Lee Lin, M.D., Ph.D., president and chief executive officer of Cue Biopharma. “The CUE-221 license agreement augments our portfolio and opportunities and the higher expenditures this quarter reflect expected one-time non-cash items and payments related to the transaction. Combined with our recent CUE-221 IND submission, financing with high-quality investors, and strategic leadership additions, we believe we are well positioned for the next phase of execution. We look forward to anticipated CUE-221 Phase 2 data by the end of this quarter and remain on track to initiate a CUE-401 Phase 1 study by the end of the year.”

Business, Financial and Leadership Highlights

Milestones

CUE-221

  • Recently submitted an IND to the FDA in food allergy applications

  • Phase 2 data readout in Chronic Spontaneous Urticaria anticipated by the end of the third quarter of 2026

CUE-401

  • Company anticipates submitting an IND to the FDA and initiating a Phase 1 clinical study by year-end 2026

Financial and Corporate

  • Completed a private placement for gross proceeds of $50 million primarily to support clinical development, pipeline advancement, and infrastructure growth

Leadership

  • Dr. Dominic Borie, Chief Medical Officer and Head of Research and Development, physician-scientist and immunology leader with deep expertise in immunology, joined Cue to help advance key clinical programs in allergic and autoimmune diseases

  • Mr. James M. Ahlers, Chief Financial Officer, a veteran biotechnology finance executive, joined Cue to help strengthen the Company’s financial leadership and the infrastructure needed to support execution of its corporate strategy

Second Quarter 2026 Financial Results

Second quarter revenue was $7.9 million, compared to $3.0 million in the second quarter of 2025. The increase in 2026 was due to revenue earned from the Boehringer Ingelheim collaboration and license agreement upon achievement of a preclinical milestone, triggered in the second quarter of 2026.

Research and development expenses were $49.0 million for the three months ended June 30, 2026, compared to $7.9 million in 2025. The increase primarily consisted of one-time cash payments of approximately $20.0 million, including the upfront payment to Ascendant and transaction-related costs. Additionally, approximately $20.0 million of expense was recognized as the fair value of warrants issued to Ascendant pursuant to the license agreement, with a corresponding credit to shareholders’ equity resulting in no net impact on stockholders’ equity.

General and administrative expenses were $46.6 million for the three months ended June 30, 2026, compared to $3.7 million in 2025. The increase was primarily attributable to one-time expenses incurred in connection with the Company’s strategic transformation, including approximately $23.0 million related to integration with a newly assembled, complementary management team and transaction-related costs, as well as approximately $19.7 million of non-cash stock-based compensation expense recognized during the quarter.

Other income and expense for the three months ended June 30, 2026, primarily comprised a net non-cash loss of $63.1 million related to the license agreement with Ascendant. As a result, a loss on issuance of liability-classified warrants was recognized, partially offset by a gain on the fair value measurement of warrants issued.

Net loss for the three months ended June 30, 2026 was $153.1 million, compared to $8.5 million in 2025. The increase was primarily due to one-time non-cash losses accounted for in other income, and one-time expenses related to the license agreement.

        

As of June 30, 2026, the Company had $17.4 million in cash and cash equivalents after incurring one-time cash outflows related to the license agreement. Subsequent to June 30, 2026, the Company completed a $50 million private placement financing.

| | | | | | | | | | | | | | | | |

| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |

| Cue Biopharma, Inc. Condensed Consolidated Statements of Operations (Unaudited; In thousands, except share and per share amounts) | | | | | | | | | | | | | | | |

| | | | | | | | | | | | | | | | |

| | Three Months Ended June 30, | | | | | | | | Six Months Ended June 30, | | | | | | |

| | | 2026 | | | | 2025 | | | | 2026 | | | | 2025 | |

| Collaboration revenue | $ | 7,877 | | | $ | 2,954 | | | $ | 13,563 | | | $ | 3,374 | |

| Operating expenses: | | | | | | | | | | | | | | | |

| General and administrative | | 46,565 | | | | 3,679 | | | | 50,717 | | | | 7,852 | |

| Research and development | | 49,007 | | | | 7,910 | | | | 55,904 | | | | 16,457 | |

| Gain on lease termination | | — | | | | — | | | | (10 | ) | | | — | |

| Total operating expenses | | 95,572 | | | | 11,589 | | | | 106,611 | | | | 24,309 | |

| Loss from operations | | (87,695 | ) | | | (8,635 | ) | | | (93,048 | ) | | | (20,935 | ) |

| Other income (expense): | | | | | | | | | | | | | | | |

| Interest income | | 157 | | | | 198 | | | | 336 | | | | 368 | |

| Interest expense | | (5 | ) | | | (45 | ) | | | (9 | ) | | | (172 | ) |

| Loss on issuance of liability-classified warrants and related issuance costs | | (90,011 | ) | | | — | | | | (90,011 | ) | | | — | |

| Changes in fair value of financial instruments | | 24,487 | | | | — | | | | 24,487 | | | | — | |

| Total other income (expense), net | | (65,372 | ) | | | 153 | | | | (65,197 | ) | | | 196 | |

| Net loss | $ | (153,067 | ) | | $ | (8,482 | ) | | $ | (158,245 | ) | | $ | (20,739 | ) |

| Net loss per common share – basic and diluted | $ | (24.14 | ) | | $ | (2.67 | ) | | $ | (28.39 | ) | | $ | (7.33 | ) |

| Weighted average common shares outstanding – basic and diluted | | 6,340,844 | | | | 3,181,980 | | | | 5,574,272 | | | | 2,828,568 | |

| | | | | | | | |

| --- | --- | --- | --- | --- | --- | --- | --- |

| Cue Biopharma, Inc. Condensed Consolidated Balance Sheets (Unaudited, In thousands) | | | | | | | |

| | | | | | | | |

| | June 30, 2026 | | | | December 31, 2025 | | |

| Assets | | | | | | | |

| Cash and cash equivalents | $ | 17,392 | | | $ | 27,136 | |

| Other assets | | 13,315 | | | | 15,076 | |

| Total assets | $ | 30,707 | | | $ | 42,212 | |

| Liabilities and stockholders’ equity | | | | | | | |

| Liabilities | $ | 28,397 | | | $ | 15,780 | |

| Stockholders’ equity | | 2,310 | | | | 26,432 | |

| Total liabilities and stockholders’ equity | $ | 30,707 | | | $ | 42,212 | |

Prompts

Cue Biopharma, Inc. (ticker CUE), listed in United States.

Company History

Date Change Detail
Dec 22, 2016 Renamed Imagen Biopharma, Inc. → CUE BIOPHARMA, INC.

ETFs Holding Cue Biopharma, Inc.

ETF Weight in ETF Shares Market value As of
AVSC 0.00% 301 $ 4,244.10 Nov 16, 2026